Highly selective HPK1 inhibitor NDI-101150 mediates immune cell activation and robust antitumor responses, distinct from immune checkpoint blockadeDavid Ciccone, Christine Loh, Peter J. Tummino et al.|Journal for ImmunoTherapy of Cancer|2025Cited by 8
Abstract 2894: NTX-452: a non-covalent, potent, selective and highly efficacious WRN inhibitor with best-in-class potential for the treatment of MSI-H tumorsRobert Svensson, Peter J. Tummino, Scott Boiko et al.|Cancer Research|2025Cited by 5
356 (PB344): Preclinical characterization of NTX-452, a potent, selective and highly efficacious WRN inhibitor for the treatment of MSI-H tumorsScott Boiko, Robert Svensson, Di Li et al.|European Journal of Cancer|2024Cited by 0